RNA interference, due to its target specificity, may be highly effective as a novel therapeutic modality, but direct delivery of synthetic small interfering RNA still remains a major obstacle for this approach. To induce long-term expression and specific gene silencing, novel delivery vector system is also required. In this study, we have generated an efficient oncolytic adenovirus (Ad)-based short hairpin (shRNA) expression system (Ad-DB7-U6shIL8) against IL-8, a potent proangiogenic factor. To demonstrate IL-8-specificity of this newly engineered Ad-based shRNA, we also manufactured replication-incompetent Ads (Ad-DE1-CMVshIL8 and Ad-DE1-U6shIL8) under the control of the cytomegalovirus (CMV) and U6 promoters, respectively. Ad-DE1-U6shIL8 was highly effective in reducing IL-8 expression, and was much more effective in driving IL-8-specific shRNA than the CMV promoter-driven vector. The reduced IL-8 expression then translated into decreased angiogenesis in vitro as measured by migration, tube formation and rat aortic ring sprouting assays. In addition to its effect on endothelial cells, Ad-DE1-U6shIL8 also effectively suppressed the migration and invasion of cancer cells. In vivo, intratumoral injection of Ad-DB7-U6shIL8 significantly inhibited the growth of Hep3B and A549 human tumor xenografts. Histopathological analysis of Ad-DB7-U6shIL8-treated tumors revealed an increase in apoptotic cells and a reduction in vessel density. Finally, Ad-DB7-U6shIL8 was also shown to inhibit the growth of disseminated MDA-MB-231 breast cancer metastases. Taken together, these findings demonstrate the utility and antitumor effectiveness of oncolytic Ad expressing shRNA against IL-8. Gene Therapy (2008) 15, 635-651;
Introduction
Angiogenesis, the formation of new capillaries from existing blood vessels, plays an important role in the growth, metastasis and malignancy of tumors. 1 A number of growth factors have been identified as positive regulators of angiogenesis. 2 While interleukin-8 (IL-8), a member of the CXC chemokine family, was initially discovered as a leukocyte chemo-attractant, recent studies have revealed that IL-8 plays an important role as a potent proangiogenic factor. 3, 4 IL-8 is produced by various tumors, including melanoma, lung, prostate, gastric, ovarian and bladder cancers. 5 Experimental and clinical studies have shown positive correlations between IL-8 expression and tumor growth and metastasis. 6 Recently, it has been shown that a blockade of IL-8 activity using a neutralizing antibody or an IL-8 antisense oligodeoxynucleotides inhibited both the growth and metastasis of tumors in a variety of animal models. [7] [8] [9] RNA interference (RNAi) is a sequence-specific, post-transcriptional gene silencing mechanism in a wide range of organisms. Triggered by a double-stranded RNA (dsRNA), it causes degradation of mRNA homologous in sequence to the dsRNA. RNAi has been reported in a variety of organisms, including plants, Caenorhabditis elegans and Drosophila. [10] [11] [12] In 1998, Fire et al. 13 reported that in the C. elegans system, dsRNA molecules inhibited translation of targeted mRNA more efficiently than individual single-stranded RNAs, and the resulting phenotype was apparently inheritable by its progeny. Exogenous dsRNA is processed into 19-to 23-nt small interfering RNAs (siRNAs) by a worm enzyme, Dicer. Incorporation of these siRNAs into an RNAinduced silencing complex is required for the posttranscriptional recognition and subsequent degradation of homologous mRNAs.
Recently, significant advances in RNAi-mediated knockdown technology have been made, and plasmid and viral vectors expressing short hairpin RNAs (shRNAs) have been developed for transient or longterm cellular expression of siRNA. Previously, our group developed an E1A-and E1B-double mutant replicationcompetent adenovirus (Ad), Ad-DB7, which elicited markedly enhanced cancer cell-specific cytotoxicity and viral replication.
14 One clear benefit of this system is its potential for amplification, where the replicating vector could infect and deliver therapeutic gene of interest to adjacent cancer cells, thus greatly enhancing the therapeutic potential.
In this study, we investigated the potential of an oncolytic Ad-mediated shRNA expression targeted to IL-8 in inhibiting both tumor growth and angiogenesis. Moreover, we compared two promoters, cytomegalovirus (CMV) and U6, in their efficiency of siRNA expression. Our results show that the U6 promoter is superior to CMV in its ability to express shRNA specific to IL-8, and that the expression of IL-8-specific shRNA can strongly and specifically silence IL-8 mRNA and protein expression in various human cancer cell lines. We show for the first time that IL-8-specific shRNA expressed from an oncolytic Ad can induce potent antiangiogenic effects, resulting in inhibition of tumor growth and metastasis. We further show that E1A-mediated suppression of angiogenesis and induction of apoptosis in tumors likely contribute to additional antitumor activity, leading to enhanced therapeutic efficacy. Findings from this study strongly suggest that the use of cancer cell-specific replicating oncolytic Ad in the delivery of IL-8-specific shRNA may hold strong promise for the treatment of cancer.
Results
Identification of effective siRNA sequences and generation of replication-incompetent Ads expressing shRNA specific to IL-8
To identify siRNA-effective sequences against IL-8, we examined four siRNAs targeting different regions of human IL-8 mRNA (gi: 28610153) as described in Table 1 . These four sequences had been confirmed to be homologous only to human IL-8 mRNA using the Blast search engine (National Center for Biotechnology Information). Of the various cancer cell lines assessed, Hep3B expressed the highest IL-8 levels (data not shown). To evaluate possible off-target effects, Hep3B cells were also transfected with siRNA specific to lamin A/C and luciferase. Relative amounts of IL-8 were measured by semi-quantitative reverse transcription-PCR, normalized to b-actin. As shown in Figure 1a , of the four siRNAs synthesized, IL-8 siRNA no. 2 (194-212) most potently suppressed the expression of IL-8 mRNA (490%). Transfection with lamin A/C-and luciferase-specific siRNA resulted in no significant alteration of IL-8 RNA expression compared to non-transfected Hep3B cells. On the basis of these results, IL-8 siRNA no. 2 was chosen to generate shRNA specific to IL-8 for use in subsequent experiments.
Recent reports have highlighted the importance of using appropriate promoters to efficiently drive the expression of siRNA. [15] [16] [17] As such in this study, two IL-8-specific shRNA-expressing replication-incompetent Ads, Ad-DE1-U6shIL8 and Ad-DE1-CMVshIL8 ( Figure  1b) , were constructed to express shRNAs under the control of the murine U6 promoter (RNA polymerase IIIdependent promoter) and the CMV promoter (RNA polymerase II-dependent promoter), respectively. For the construction of shRNA, shRNA expression cassette from the pSUPER vector was used. 12 The 19-nt IL-8-specific targeting sequence, separated by a 9-nt short spacer and including five thymidines (T5) as a termination signal was annealed and cloned into the pdl-DE1 adenoviral total vector, generating Ad-DE1-U6shIL8 and Ad-DE1-CMVshIL8.
Comparison of U6 and CMV promoters in IL-8 knockdown in vitro
To compare promoter efficiency in the knock down of IL-8 expression, a panel of cancer cell lines (Hep3B, Huh7, Hep1, HepG2, MDA-MB-231, U87, U251N, U343 and A549) was transduced with Ad-DE1, Ad-DE1-CMVshIL8 or Ad-DE1-U6shIL8 at various multiplicity of infections (MOIs). Non-transduced cell lines were also used as negative controls. After 72 h, conditioned media was harvested and an IL-8 enzyme-linked immunosorbent assay (ELISA) was carried out. As shown in Figure  2a , the synthesis and secretion of IL-8 was significantly reduced by Ad-DE1-U6shIL8. In Hep3B cells, IL-8 levels were decreased by 73.7 and 73.4% (Po0.05 and Po0.05) compared to non-transduced and control Ad-DE1-transduced cells, whereas the reduction was only 8.2 and 7% with Ad-DE1-CMVshIL8. This result is in agreement with a previous finding that RNA polymerase II promoters such as CMV promoter are not efficient to drive shRNA. 18 This efficient knock down of IL-8 by Ad-DE1-U6shIL8 was also observed in each of the other cancer cell lines tested. Moreover, Ad-DE1-U6shIL8 strongly silenced IL-8 expression even at low MOIs, whereas a notably higher MOI of Ad-DE1-CMVshIL8 was needed for effective knockdown (Figure 2b ). Despite the reduction in endogenous IL-8 protein secretion by Ad-DE1-U6shIL8-transduced cancer cells, the growth rate of these cells was not different from cells transduced with Ad-DE1 (data not shown). Taken together, these data show that IL-8-specific shRNA-expressing Ads reduce IL-8 expression, and, more importantly, that the U6 promoter is much more effective in driving IL-8-specific shRNA expression than the CMV promoter.
Effect of IL-8-specific shRNA expression on the function of endothelial cells in vitro
We investigated the effects of Ad-mediated IL-8-specific shRNA expression on the migration of human umbilical vein endothelial cells (HUVECs) in vitro. Conditioned medium from A549 cells transduced with Ad-DE1-U6shIL8 reduced the migration of endothelial cells by 48.8% (Po0.001 compared to Ad-DE1). In comparison, conditioned medium from Ad-DE1-CMVshIL-8-transduced cells inhibited migration only 24% (Po0.05 compared to Ad-DE1) (Figure 3a) . Nearly identical results were observed using conditioned medium from Hep3B cell lines. Oncolytic adenovirus expressing shRNA specific to IL-8
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We then assessed the functional effect of Ad-mediated IL-8-specific shRNA expression on capillary tube formation in vitro. HUVEC cells seeded onto Matrigel-coated plates were incubated in the presence of medium supplemented with human recombinant rVEGF 165 protein (10 ng ml
À1
) or with conditioned medium from Ad-DE1-, Ad-DE1-CMVshIL8-or Ad-DE1-U6shIL8-transduced cells. As shown in Figure 3b , conditioned medium from Ad-DE1-U6shIL8-transduced cells effectively inhibited HUVEC tube formation, whereas rVEGF 165 and conditioned media collected from Ad-DE1-and Ad-DE1-CMVshIL8-transduced cells resulted in the formation of robust, elongated tube-like structures, which were organized in much larger numbers of cells. In particular, conditioned medium from Ad-DE1-U6shIL8-transduced cells diminished relative tube length by 65.5% (Po0.001 compared to Ad-DE1; Figure 3c ).
As angiogenesis involves multiple processes, we assessed inhibition of vessel sprouting using rat aortic rings (explants) embedded in Matrigel beds. The Matrigel bed mimics a physiological extracellular matrix, representing its natural composition and architecture. Because of these features, Matrigel enables several cell types, including endothelial cells, to maintain their threedimensional, in vivo phenotype in culture. Microvessel sprouting was demonstrated by staining aortic rings with Diff-Quick, as described in Materials and methods. As shown in Figures 3d and e, a marked delay in the outgrowth of sprouts from explants, with a regression in both the number of microvessels and the number of branches, was observed in aortic rings treated with conditioned medium from Ad-DE1-U6shIL8-transduced cells, showing a decrease in the number of microvessels of 68.2% (Po0.001) and 65% (Po0.001) compared to Oncolytic adenovirus expressing shRNA specific to IL-8 JY Yoo et al untransduced and Ad-DE1-transduced conditioned media, respectively. In contrast, neither Ad-DE1 nor Ad-DE1-CMVshIL8 had an inhibitory effect on microvessels sprouting from aortic rings. In fact, the extent of the capillary network was comparable to that observed in the presence of conditioned medium from untransduced cells. These data further confirm the potent inhibition of angiogenesis induced by Ad-DE1-U6shIL8. Oncolytic adenovirus expressing shRNA specific to IL-8 JY Yoo et al MMP family members, MMP-2 plays a critical role in the angiogenic switch during carcinogenesis. By using conventional gelatin zymography, we compared gelatinolytic activity of MMP-2 in response to Ad-DE1-, Ad-DE1-CMVshIL8-and Ad-DE1-U6shIL8-transduced U343 and U251N cancer cells. As shown in Figure 4c , MMP-2 gelatinolytic activity was reduced in Ad-DE1-U6shIL8-transduced cells, whereas Ad-DE1-or Ad-DE1-CMVshIL8-transduced cancer cells showed MMP-2 activity similar to the levels observed for parental cells. ELISA quantitation of MMP-2 protein in A549 cancer cells transduced with Ad-DE1-U6shIL8 indicated that a reduction in the MMP-2 protein level closely paralleled the observed loss of MMP-2 gelatinolytic activity (Figure 4d ). These results strongly suggest that Ad-DE1-U6shIL8 inhibits invasion of cancer cells, presumably through the inhibition of MMP-2 activity.
Generation and characterization of oncolytic Ad expressing shIL-8
Although the siRNA method is a powerful genetic tool for targeting specific gene expression, direct delivery of synthetic siRNA is challenging. We therefore investigated whether shRNAs can be delivered and, more importantly, maintain functional relevance in cancer cells using replication-competent oncolytic Ad. Previously, we constructed a cancer-specific, replicating E1A-mutated (at the retinoblastoma-binding sites of E1A) and E1B-deleted Ad, Ad-DB7. Ad-DB7 showed significantly improved cytopathic effects and viral replication in a cancer cell-specific manner.
14 To induce long-term IL-8 silencing, we introduced shIL-8 under the control of CMV and U6 promoters at the E3 region of Ad-DB7, generating Ad-DB7-CMVshIL8 and Ad-DB7-U6shIL8 oncolytic Ad, respectively ( Figure 1c ).
To determine whether virally expressed shIL-8 altered viral replication, the newly engineered Ads were first examined for their potential to induce cytopathic effects. Multiple cancer cells (A549, U343, Hep1, MDA-MB-231, U87 and Hep3B) were infected with Ad-DB7, Ad-DB7-CMVshIL8, or Ad-DB7-U6shIL8 at MOIs of 0.1-20. As a negative control, cells were infected in parallel with replication-incompetent Ad, Ad-DE1. As seen in Figure  5a , virally induced cytopathic effects appeared to be similar with Ad-DB7-CMVshIL8 and Ad-DB7-U6shIL8 as compared to Ad-DB7. This result was consistent over several independent experiments, suggesting that shIL-8 expression does not inhibit viral replication.
Next, we examined whether shIL-8-expressing oncolytic Ads can functionally knockdown IL-8 expression. Hep3B, A549 and MDA-MB-231 cells were infected with Ad-DB7, Ad-DB7-CMVshIL8 or Ad-DB7-U6shIL8. As shown in Figure 5b , significant suppression of IL-8 expression by Ad-DB7-U6shIL8 oncolytic Ad was observed in all cell lines (Hep3B, A549 and MDA-MB-231) with 62.1% (Po0.001 versus Ad-DB7), 53.4% (Po0.001 versus Ad-DB7) and 60.5% (Po0.001 versus Ad-DB7) decrease in IL-8 protein levels, respectively. To demonstrate IL-8 specificity of Ad-DB7-U6shIL8, cells were also infected with Ad-DB7-U6shVEGF, an oncolytic Ad expressing VEGF-specific shRNA under the control of This is in agreement with ours' and other investigators' previous findings that E1A expression suppresses tumor angiogenesis. [19] [20] [21] Taken together, these data demonstrate that oncolytic Ad-DB7-U6shIL8 reduced IL-8 expression with high degree of efficiency as well as high specificity. Oncolytic adenovirus expressing shRNA specific to IL-8 JY Yoo et al
Oncolytic Ad expressing shIL-8 inhibits tumor growth in nude mice
Since Ad-DB7-U6shIL8 exhibited greater IL-8-suppressive effect than Ad-DB7-CMVshIL8, oncolytic Ad-DB7-U6shIL8 was chosen to examine its effect in vivo. Hep3B and A549 tumor models established in nude mice showed aggressive growth kinetics. When tumors reached an average size of 100 mm 3 , tumors were injected intratumorally with phosphate-buffered saline (PBS), Ad-DB7 or Ad-DB7-U6shIL8 every 2 days for a total of three injections (Q2D Â 3). As seen in Figure 6a , tumor volume was greatly reduced in mice treated with both oncolytic Ads (Ad-DB7 and Ad-DB7-U6shIL8) compared to control mice treated with PBS. At 35 days after viral treatment, tumors of Hep3B tumor-bearing mice treated with PBS reached an average tumor volume of 3672±575 mm 3 and the average tumor volumes for the Ad-DB7 and Ad-DB7-U6shIL8 groups were 942.68 ± 107 and 335.61 ± 91 mm 3 , respectively. Similarly, mice bearing A549 tumor xenograft showed tumor growth inhibition of 91.7% (Po0.001) in response to Ad-DB7-U6shIL8 treatment. Throughout the course of the study, no systemic toxicity, such as diarrhea, loss of weight or cachexia was observed. These data indicate that suppression of IL-8 expression by oncolytic Ad had strong inhibitory effects on the growth of these tumor xenografts.
The histology of tumors obtained 7 days post-final dose was then observed. As shown in Figure 6b , hematoxylin and eosin (H&E) staining of A549 tumors treated with Ad-DB7-U6shIL8 showed dramatic effects as only the number of viable tumor cells was observed. In addition, apoptotic changes and cell necrosis, replaced by stromal fibrosis, were also seen. Masson's trichrome staining determined collagen type I, stained in blue, as the predominant morphological component of these fibrotic changes. Microvessel density was then examined by immunostaining with anti-PECAM (anti-CD31) antibody. A marked decrease in endothelial cells and vessel structures was observed in Ad-DB7-U6shIL8-treated tumors compared to PBS-or Ad-DB7-treated tumors. Ad-B7-U6shIL8
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Quantitation of microvessels showed that the density was reduced by 44.7% (Po0.05) and 50.6% (Po0.05) in Hep3B and A549 xenograft models, respectively, compared to Ad-DB7 (Figures 6b and c) . To analyze the degree to which Ad-DB7-U6shIL8 induced apoptosis in vivo, terminal uridine deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was carried out using the same tumor sections. As seen in Figure 6b , the level of apoptosis was considerably higher in Ad-DB7-U6shIL8-treated tumor tissue than in PBS-or Ad-DB7-treated tumor tissue. This result closely parallels and supports the decreased neovascularization in the tumor mass and enhanced antitumor effect of IL-8-specific shRNA-expressing oncolytic Ad.
To investigate the biological significance of IL-8 downregulation in tumor tissue, we assessed IL-8 and Activation of angiogenesis is also responsible for increased tumor cell entry into circulation and metastasis. Therefore, we investigated whether suppression of IL-8 would have an effect in blocking pulmonary metastasis of a malignant human breast cancer cell line, MDA-MB-231. Administration of Ad-DB7-U6shIL8 resulted in a marked reduction of metastatic burden (Figure 7a ). More specifically, three of seven mice showed no metastatic spread and the remaining four exhibited minimal tumor spread as compared to control animals treated with PBS or Ad-DB7. Moreover, histological examination of the pulmonary tissue from PBStreated mice showed a large number of sizable tumor mass consisting of viable metastasized MDA-MB-231 cells. In contrast, the Ad-DB7-U6shIL8-treated mice showed a marked reduction in metastatic lesions, of which the remaining tumor mass consisted mainly of necrotic cells (Figure 7b ). Masson's trichrome staining also revealed that most remaining tumor tissues treated with Ad-DB7-U6shIL8 were replaced by stromal fibrosis. The antiangiogenic effect of IL-8-specific shRNAexpressing oncolytic Ad on pulmonary metastasis was further verified by immunohistochemical analysis with an endothelial cell-specific surface marker (CD31) in the tumor nodules. As shown in Figure 7c , microvessel density was reduced by 97.9% (Po0.001) and 87.5% (Po0.001) in response to Ad-DB7-U6shIL8 Ad treatment as compared to PBS and Ad-DB7 Ad treatment groups, respectively. More importantly, adenoviral particles were detected in Ad-DB7-and Ad-DB7-U6shIL8-treated tumors using anti-E1A antibody, supporting active viral replication in the lung tumor nodules. Taken together, these results indicate that the suppression of IL-8 by oncolytic Ad strongly inhibited pulmonary tumor metastasis.
Since the observed toxicities associated with preclinical and clinical Ad-mediated gene therapy have been localized to hepatic, renal and hematologic origin, blood was evaluated for aspartate aminotransferase, alanine aminotransferase, T-bilirubin, creatinine, blood urea nitrogen and lactate dehydrogenase. The results are summarized in Table 2 . Oncolytic Ads at a dose of 5 Â 10 8 PFU injected into pleural cavity did not significantly increase the level of aspartate aminotransferase, alanine aminotransferase, T-bilirubin, creatinine, blood urea nitrogen and lactate dehydrogenase when assessed at 3 or 28 days post-final viral injection. Furthermore, no specific abnormalities in general appearance and microscopic examination were observed. These results indicate that the administration of Ad-DB7-U6shIL8 onto the pleural cavity is safe and well tolerated.
Discussion
RNAi has emerged as an important tool in downregulating sequence-specific gene expression at both the transcriptional and post-transcriptional levels. In mammalian systems, sequence-specific RNAi effects can easily be achieved by introducing synthetic siRNAs via transfection. 22, 23 However, their use in a therapeutic Oncolytic adenovirus expressing shRNA specific to IL-8 JY Yoo et al setting has been limited, mainly due to its short half-life in vivo. To overcome these limitations, siRNA-mediated specific gene silencing has been developed using plasmids or viral vectors designed to drive the expression of siRNAs. Wyatt et al. 25 reported that an MMP-1-specific siRNA-expressing plasmid selectively blocked MMP-1 expression in MDA-231 breast cancer cells, which have constitutively high levels of MMP-1. In 2004, Yang et al. 26 demonstrated that expression of Her-2/neu can be silenced through retrovirus-mediated transfer of a Her-2/neu-specific siRNA. Ads-mediated siRNA specific to Hec1 has also been shown to inhibit tumor growth in vivo. 27 These studies have demonstrated that siRNA-mediated 'reverse genetics' can open new avenues as a novel therapeutic strategy in combating cancer.
Most shRNA-expressing vectors have used RNA polymerase III promoters (U6, H1 or 7SK). Polymerase III promoters have the advantage of directing the synthesis of small, non-coding transcripts whose 3 0 ends are defined by termination within a stretch of 4-5 thymidines. 17, 24 Synthesis of shRNAs from a single DNA template driven by polymerase III promoters has made it possible to develop plasmids and virus-derived vectors as RNAi-delivery vehicles. In addition to mRNA, polymerase II promoters synthesize many non-coding RNAs, including small nuclear and nucleolar RNAs. Although the polymerase II promoter-based shRNA system has also been reported to be effective, 2, 18, [28] [29] [30] no information is yet available on whether polymerase III promoters are superior to polymerase II promoters in their ability to express shRNA. To explore the utility of RNA polymerase II promoters for expression of shRNAs, we initially constructed two replication-incompetent Ads, Ad-DE1-U6shIL8 and Ad-DE1-CMVshIL8, which express IL-8-specific shRNA under the control of the U6 and CMV promoters, respectively. As demonstrated in Figure 2 , Ad-DE1-U6shIL8 was highly effective in reducing IL-8 expression, whereas no significant gene silencing was achieved with the CMV promoter-driven Ad in various cancer cell lines. Moreover, a 10-fold greater Ad-DE1-CMVshIL8 viral dose is needed to suppress IL-8 expression to the extent elicited by Ad-DE1-U6shIL8 transduction (Figure 2b ). This finding concurs with recent reports that an unmodified CMV promoter is inefficient at gene silencing through shRNA expression. 31, 32 Xia et al. and Zhou et al. [32] [33] [34] have demonstrated that the placement of the hairpin immediately adjacent to the transcription start site and use of a minimal polyadenylation cassette are highly critical in driving shRNA expression. RNA polymerase II promoters are very valuable in both biomedical research and clinical applications, such as gene therapy, because they allow inducible, tissue-specific or cell-type-specific RNA expression. 35, 36 Therefore, design and optimization of polymerase II promoters that effectively drive shRNA expression would be very beneficial.
Endothelial cell migration, tube formation and vessel sprouting are required for the angiogenic process, and acquisition of an angiogenic phenotype is crucial for tumor progression. Therefore, we investigated whether IL-8-specific shRNA expressed from an Ad could inhibit migration and differentiation of HUVEC into the capillary-like structures of precursory vessels. Addition of conditioned media from Ad-DE1-U6shIL8-transduced cells in transwell migration assays suppressed migration of endothelial cells by more than 48% relative to conditioned media from Ad-DE1-transduced cells (Figure 3) . The ability of endothelial cells to form tubes on a matrix and of microvessels to sprout from rat aorta rings was also effectively inhibited by Ad-DE1-U6shIL8. These results demonstrate that Ad-mediated expression of IL-8-specific shRNA is functionally active and acts on endothelial cells to block several critical steps in angiogenesis. In addition to inhibition of endothelial cell function, Ad-DE1-U6shIL8 effectively suppressed migration and invasion of cancer cells (Figure 4) . Moreover, in gelatin zymography and ELISA assays, expression of IL-8-specific shRNA reduced both the expression and activity of MMP-2. MMPs appear to play a crucial role in many stages of tumor progression, including angiogenesis and the invasion and metastasis of tumor cells. Studies by Bergers et al. 37 and Blavier et al. 38 have also reported that MMP-2 is upregulated in angiogenic lesions and plays an active role during carcinogenesis of Wnt1-induced mammary tumors in transgenic mice. Downregulation of MMP-2 may thus be directly responsible for inhibition of cellular locomotion and invasive ability in vitro and may play a role in angiogenesis inhibition in vivo.
We next determined whether oncolytic Ad expressing IL-8-specific shRNA could functionally reduce endogenous IL-8 expression in cancer cells. We and others have previously shown that replication-competent Ad suppresses tumor angiogenesis through the preserved E1A region. [19] [20] [21] In agreement with these previous results, we observed that control oncolytic Ad that does not express IL-8-specific shRNA (Ad-DB7) substantially suppressed IL-8 expression compared to E1A-deleted replicationincompetent Ad (Ad-DE1). Interestingly, Ad-DB7-U6shIL8 Moreover, treatment with Ad-DB7-U6shIL8 markedly inhibited the growth of established Hep3B and A549 xenograft tumors in nude mice and significantly delayed morbidity related to large tumor size. To better understand the mechanism of action of Ad-DB7-U6shIL8, microvessel density was assessed using an anti-CD31 antibody. Tumor angiogenesis was found to be significantly suppressed in Ad-DB7-U6shIL8-treated mice versus control mice or mice treated with Ad-DB7 in both xenograft models. In view of these data, we conclude that inhibition of tumor growth is caused, in part, by the reduced number of tumor vessels in Ad-DB7-U6shIL8-treated mice. The antitumor efficacy of Ad-DB7-U6shIL8 was not limited to subcutaneous tumor xenograft models, but was also evident in a metastatic tumor model where intrapleural injection of Ad-DB7-U6shIL8 inhibited the growth of disseminated MDA-MB-231 breast cancer metastases. These findings suggest that in addition to affecting the growth of a localized primary tumor, Ad-DB7-U6shIL8 is also able to inhibit the dissemination and/or growth of distant metastases.
In addition to inhibitory effects on endothelial cells and in vivo and in vitro angiogenesis, Ad-DB7-U6shIL8 also inhibited secretion of two angiogenic factors, VEGF and IL-8, suggesting that the expression of these signal modulators is affected in vivo. These results further confirmed and extended our in vitro observations of angiogenic regulation by IL-8-specific shRNA expression. Angiogenesis is the result of an intricate balance between proangiogenic and antiangiogenic factors, and, accordingly, downregulating the synthesis of potent proangiogenic factors can critically shift this balance to interrupt the formation of new vessels. 39 Recently, inhibition of IL-8 activity using anti-IL-8-neutralizing antibody or IL-8 antisense oligodeoxynucleotides or by disabling the function of its receptors has been shown to inhibit both tumor growth and metastasis in a variety of animal tumor models. [7] [8] [9] Moreover, Inoue et al. 40 have demonstrated that Ad IL-8-AS therapy decreased the in vivo expression of IL-8 and MMP type 9 (MMP-9), reduced microvessel density and enhanced endothelial cell apoptosis. Therefore, the therapeutic effects in terms of inhibiting tumor growth and metastasis by inhibiting IL-8 activity or disabling the function of its receptors appear to be a promising therapeutic target for cancer. As demonstrated in Figure 6e , suppression of IL-8 by Ad-DB7-U6shIL8 may provide the initial trigger for an antiangiogenic amplification loop, with subsequent reduction of VEGF, one of the main angiogenic switch inducers. Further experiments are planned to address this observation more rigorously and to investigate the underlying mechanisms.
Since VEGF and IL-8 have been shown to act as survival factors for endothelial cells in response to radiation or chemotherapeutic agents, treatment with IL-8-specific shRNA-expressing oncolytic Ad in combination with radiation or chemotherapeutic agents may block this protective effect. 41 Furthermore, combination therapy with Ad-DB7-U6shIL8 and chemotherapeutic agents may be a useful strategy because suppression of IL-8 and VEGF may increase drug delivery to the tumor, possibly by lowering interstitial pressure, unpacking the mass of tumor cells or transforming tumor vasculature to a more 'normal' phenotype.
The duration of gene suppression is largely dependent on the rate of cell growth and turnover of the targeted protein in actively dividing cells in culture. Since cancer cells are actively dividing, the duration of siRNAmediated gene silencing in vivo might be governed by the efficiency of the siRNA-expressing vector and the stability of the functional siRNA. Oncolytic Ad-mediated siRNA expression may lead to improved efficacy over non-replicating vectors because of the self-perpetuating nature of viral multiplication and secondary infection of adjacent cells, which would replenish the pool of therapeutic siRNA molecules over time. In general, o10 000 viral progeny are generated in a single cell after viral infection. 42 Therefore, we would also expect amplification of therapeutic siRNA in a cancer cellspecific manner, as an oncolytic Ad should be able to deliver it by infecting neighboring cancer cells.
Overall, this study indicates that the use of cancer cellspecific, replicating oncolytic Ad to deliver IL-8-specific shRNA offers the potential benefits of restricted and renewable siRNA expression within the tumor microenvironment, an additive antitumor outcome through viral oncolysis and siRNA-mediated IL-8 silencing. In addition, our data provide the first evidence that siRNA directed against IL-8, delivered by oncolytic Ad directly into the tumor, has the ability to downregulate the target gene and can suppress the progression of human cancer xenografts in mice.
Materials and methods

Cell lines and cell culture
All cell lines with the exception of Hep3B, which was maintained in modified Eagle's medium (Gibco BRL, Grand Island, NY, USA), were cultured in Dulbecco's modified Eagle's medium (Gibco BRL) supplemented with 10% fetal bovine serum (FBS; Gibco BRL), Lglutamine (2 mM), penicillin (100 IU ml
À1
) and streptomycin (50 mg ml À1 ). A human embryonic kidney cell line expressing the Ad E1 region (HEK293), brain cancer cell lines (U343, U251N and U87MG), liver cancer cell lines (Hep3B, HepG2, Huh7 and Hep1), breast cancer cell line (MDA-MB-231) and a non-small lung cancer cell line (A549) were purchased from American Type Culture Collection (Manassas, VA, USA). HUVECs, isolated from human umbilical cord veins by collagenase treatment as described previously, 43 were maintained and propagated in M199 medium (Invitrogen, Carlsbad, CA, USA) containing 20% FBS, penicillin-streptomycin (100 IU ml À1 ), 3 ng ml À1 basic fibroblast growth factor (Upstate Biotechnology, Lake Placid, NY, USA) and 5 U ml heparin. HUVECs were used between passages 2 and 7. All cell lines were maintained at 37 1C in a humidified atmosphere at 5% CO 2 .
Synthesis and transfection of siRNAs specific for IL-8
Four synthetic double-stranded oligonucleotides, corresponding to four 21-nt sequences from human IL-8 (GenBank accession number gi: 28610153), were designed using RNAi software (Ambion: www.ambion. com/techlib/misc/siRNA_finder.html) and synthesized Oncolytic adenovirus expressing shRNA specific to IL-8 JY Yoo et al using the Ambion Silencer siRNA construction kit (Cat. no. 1620; Table 1 ). To determine the most effective siRNA, 1 mg of each of the four synthesized siRNAs and two control siRNAs specific to lamin A/C and luciferase were introduced into Hep3B cells (3 Â 10 5 ) in six-well dishes using lipofectamine plus reagent (Invitrogen). After 48 h, cells were harvested and total RNA was extracted using the RNeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Semi-quantitative reverse transcription-PCR was then performed using b-actin as an internal control to normalize gene expression.
Generation of IL-8-specific shRNA-expressing Ads
To generate Ads expressing IL-8-specific shRNA, DNA fragment targeting position 194-212 of human IL-8 was first generated by annealing the sense oligonucleotide 5 0 -gatcccGAACTTAGATGTCAGTGCATAttcaagagaAAT ATGCACTGACATCTAAGTtttttggaaa-3 0 and its cognate antisense oligonucleotide 5 0 -agcttttccaaaaaaGAACTTA GATGTCAGTGCATAtctcttgaaAATATGCACTGACATC TAAGTgg-3 0 . The 19-nt IL-8 target sequences are indicated in uppercase letters, whereas the 9-nt hairpin and sequences necessary for directional cloning are depicted in lowercase letters. After annealing with sense and antisense oligonucleotides, the fragments were inserted into a pSilencer-2.1-hygro-U6 vector (Ambion), resulting in pshU6IL-8. The shIL-8 gene expression cassette excised from pshU6IL-8 was then subcloned into the pSP72-E3 Ad shuttle vector 44 using EcoRIHindIII, generating pSP72-E3/U6shIL8. In addition, the annealed IL-8-specific shRNA DNA fragment was subcloned into the pSP72-E3/CMV Ad shuttle vector, 44 generating pSP72-E3/CMVshIL8. The newly constructed pSP72-E3/U6shIL8 and pSP72-E3/CMVshIL8 E3 shuttle vectors were linearized with XmnI and co-transformed with pdl-DE1, a replication-incompetent Ad total vector expressing lacZ at E1 region, or pdl-DB7, a replicationcompetent Ad total vector, into Escherichia coli BJ5183 for homologous recombination, generating the pAd-DE1-U6shIL8, pAd-DE1-CMVshIL8, pAd-DB7-U6shIL8 and pAd-DB7-CMVshIL8 Ad vectors. The control vector (psc-shRNA) was constructed by inserting a sequence that expresses a siRNA with limited homology to sequences in the human and mouse genomes. To verify homologous recombinants, plasmid DNA purified from overnight E. coli cultures was digested with HindIII, and the digestion pattern was analyzed. Correct homologous recombinant Ad plasmid DNA was digested with PacI and transfected into 293 cells to generate Ad-DE1-U6shIL8, Ad-DE1-CMVshIL8, Ad-DB7-U6shIL8 and Ad-DB7-CMVshIL8 Ads. E1-deleted, replication-incompetent Ad (Ad-DE1), replication-competent Ad mutated in retinoblastoma-binding sites of E1A and deleted in E1B region (Ad-DB7) 14 were also prepared. All viruses were propagated using the 293 cells, and purification, titration and quality analysis of all Ads used were performed as previously described. 45 The titer (plaque-forming units per milliliter) used in this study was determined by limiting dilution assay in 293 cells.
Migration assay
The lower surface of 6.5-mm-diameter polycarbonate filters (8 mm pore size; Corning Costar, Cambridge, MA, USA) was coated by immersion in 0.1% gelatin.
Conditioned medium from cells treated with PBS, Ad-DE1 or Ad-DE1-U6shIL8 was placed in the lower part of Transwell chambers, and HUVECs, Hep3B or A549 cells were placed on the filter membrane on the top chamber. Cultures were incubated at 37 1C for 4 h, and cells remaining on the upper surface of the filter were removed with a cotton swab. Filters were stained with H&E, and cells that migrated through to the underside of the filter membrane were counted at Â 200 magnification. Ten fields were counted for each assay, and experiments were repeated at least three times.
Tube formation assay
First, 250 ml of growth factor-reduced Matrigel (Collaborative Biomedical Products, Bedford, MA, USA) was pipetted into a 16-mm-diameter tissue culture well and polymerized for 30 min at 37 1C. HUVECs incubated in M199 containing 1% FBS for 6 h were harvested after trypsin treatment and suspended in M199 containing 1% FBS. HUVECs were then plated onto the layer of Matrigel at a density of 2 Â 10 5 cells per well, and conditioned media from Ad-infected Hep3B cells were added. VEGF (Upstate Biotechnology) at 10 ng ml À1 and conditioned media from uninfected cells were used as controls. Cells were then allowed to form tubes for 20 h at 37 1C, and photographed ( Â 40 and Â 100). The area covered by the tube network was determined using an optical imaging technique in which pictures of the tubes were scanned into Adobe Photoshop and quantitated using Image-Pro Plus software (Media Cybernetics Inc., Silver Spring, MD, USA).
Ex vivo aortic ring sprouting assay
Aortas were harvested from Sprague-Dawley rats (6 weeks old), as described previously. 46 After removing the surrounding fibro-adipose tissues and rinsing with Hank's balanced salt solution buffer, aortas were cut into 1-mm ring segments. Plates (48-well) were coated with 120 ml of Matrigel; after gelling, rings were placed in the wells and sealed in place with an overlay of 50 ml of Matrigel. Conditioned media from Ad-infected cells (250 ml) were added to the wells. VEGF (20 ng ml À1 ; Upstate Biotechnology) and conditioned media from uninfected cells were used as controls. On day 6, cells were fixed and stained with Diff-Quick. Each ring was scored from 0 (least positive) to 5 (most positive) depending on the degree of vessel sprouting observed. Cultures were scored in a double-blinded manner by three independent observers.
Matrigel invasion assay
In vitro invasion assays were carried out using Transwell chambers with 6.5-mm-diameter polycarbonate filters (Corning Costar) according to the manufacturer's instructions. Conditioned media from Ad-infected cells were placed in the lower chambers and Hep3B or A549 cells (1 Â 10 5 cells 100 ml
À1
) were seeded onto Matrigelcoated filters in the upper chambers. After 24 h incubation, cells on the upper surface of the filters were removed with a cotton swab, and filters were fixed with 100% methanol and stained with H&E. Cells that had invaded to the lower side of the filters were viewed under an optical microscope. Invasive activity is expressed as the mean number of cells in 10 fields from three independent experiments.
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Gelatin zymography
The gelatinolytic activity of MMP-2 was measured by zymography. The protein content of conditioned media from cells treated with Ad-DE1, Ad-DE1-CMVshIL8 or Ad-DE1-U6shIL8 was first determined using the bicinchoninic acid method (BCA assay; Pierce, Rockford, IL, USA). Samples (20 mg) were then loaded onto 10% SDSpolyacrylamide gels containing 1 mg ml À1 gelatin. After electrophoresis, gels were soaked in renaturation buffer (2.5% Triton X-100) for 1 h to remove SDS, and incubated in developing buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 10 mM CaCl 2 ) for 16 h at 37 1C. Gels were then stained for 30 min with 1% Coomassie brilliant blue and destained with 30% methanol and 10% acetic acid for 1 h. Proteolytic activity was detected as clear bands on a blue background of the Coomassie brilliant blue-stained gel. MMP-2 was identified by size, and comparison with the respective recombinant protein used as an additional marker. Quantification was performed by Image analyzer software (WinCam 2.2; Cybertech, Berlin, Germany). All experiments were performed at least in triplicate, and representative experiments are shown.
Cytopathic effect assay
To evaluate the cytopathic effect of Ads, cells were plated onto 24-well plates at about 50-80% confluence, and then infected with Ad-DE1, Ad-DB7, Ad-DB7-CMVshIL8 or Ad-DB7-U6shIL8 Ad at MOIs of 0.1-20. Killing effect was monitored daily under a microscope. When cells infected with any one of the viruses exhibited cell lysis at low MOI, non-viable cells were washed, and remaining cells were stained with 0.5% crystal violet in 50% methanol.
Antitumor effects in human xenograft model
Human tumor xenograft Hep3B and A549 were established in 6-to 8-week-old male athymic nu/nu mice (Charles River Japan Inc., Yokohama, Japan). Mice were implanted with 1 Â 10 7 Hep3B human hepatoma and A549 human lung cancer cells subcutaneously in the abdominal region. When tumor volumes reached approximately 100 mm 3 (calculated by volume ¼ 0.523LW 2 ), animals were sorted into groups with similar mean tumor volumes and intratumoral administration of Ads or PBS was initiated. All studies were conducted in the Yonsei University College of Medicine, an Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility, according to institutional regulations.
Evaluation of tumor xenograft by histology and immunohistochemistry
Tumor tissue was fixed in formalin-free IHC zinc fixative formalin-free (BD Biosciences PharMingen, San Diego, CA, USA), embedded in paraffin and cut into 3-mm sections (Wax-it, Vancouver, BC, Canada). Representative sections were stained with H&E or with Masson's trichrome and then examined by light microscopy. For immunohistochemistry, slides were deparaffinized in xylene and then hydrated through graded alcohols. Endogenous peroxidase in the sections was blocked with 3% hydrogen peroxide. Sections were incubated with CAS-BLOCK (Zymed, San Francisco, CA, USA) for 30 min at room temperature to block nonspecific protein binding, and then the sections were incubated at 4 1C overnight with primary antibody, a monoclonal rat antimouse CD31, at a dilution of 1:50. Sections were rinsed in PBS-T (0.05% Triton X-100 (Sigma; Cat. no. T8787) in PBS), and biotinylated polyclonal anti-rat Ig (multiple adsorption) antibody (BD Biosciences PharMingen) was added at a 1:500 dilution for 1 h at room temperature. After washing twice with PBS-T, slides were subsequently incubated with streptavidin-horseradish peroxidase (BD Biosciences PharMingen). Diaminobenzidine/ hydrogen peroxidase (Dako, Carpinteria, CA, USA) was used as the chromogen substrate. All slides were counterstained with Meyer's hematoxylin. Blood vessels were counted as described previously. 47, 48 The most vascular area of tumors was identified on low-power ( Â 100) and vessels were counted in 10 high-power fields ( Â 200). The data are presented as mean±s.e. of three tumors per group.
In vivo TUNEL assay
Deparaffinized tissue sections were treated with proteinase K (20 mg ml
À1
) for 15 min, and endogenous peroxidase was blocked using 3% hydrogen peroxide in PBS for 10 min. Samples were washed three times in distilled water and incubated for 10 min at room temperature with terminal deoxynucleotidyl transferase buffer. Excess terminal deoxynucleotidyl transferase buffer was drained, and samples were incubated for 1 h at 37 1C with terminal transferase and biotin-16-dUTP. Samples were then rinsed four times with PBS and incubated for 1 h at 37 1C with a 1:400 dilution of peroxidaseconjugated streptavidin. Slides were rinsed with PBS and incubated for 5 min with 3,3 0 -diaminobenzidine. Sections were then washed three times with PBS, and counterstained with methyl green.
Quantitation of IL-8, VEGF and MMP-2 by ELISA
Concentrations of human IL-8, VEGF-A and MMP-2 in conditioned medium and tumor tissue lysates were measured using commercially available ELISA kits according to instructions provided by the vendor (IL-8: Biosource International Inc., Camarillo, CA, USA; VEGF: R&D Systems, Minneapolis, MN, USA; MMP-2: R&D Systems). Cells were plated onto six-well plates in a medium containing 10% FBS. When the cells reached subconfluence, cells were infected with Ads at different MOIs. Conditioned media were harvested 24 h after infection for replication-competent Ads and 72 h after transduction for replication-incompetent Ads. To remove endogenously expressed IL-8, VEGF and MMP-2, medium was replaced with Dulbecco's modified Eagle's medium containing 5% FBS 24 h before each respective harvest time point. Tumors obtained from mice were homogenized in ice-cold PBS with protein inhibitor cocktail (Sigma; Cat. no. P8340) and analyzed for total protein content using a BCA protein assay reagent kit (Pierce). Levels of IL-8, VEGF and MMP-2 in conditioned medium and tumor tissue extract were then determined by ELISA. Serial dilutions of purified recombinant human IL-8, VEGF-A and MMP-2 were used to establish standard curves. ELISA results were normalized relative to the total protein concentration in each sample and were calculated as picograms per milligram of total protein.
MDA-MB-231 pulmonary metastasis model
A malignant human breast cancer cell line, MDA-MB-231, was used to examine the effect of suppression of IL-8 expression on tumor metastasis. Briefly, 2 Â 10 6 MDA-MB-231 breast cancer cells per mouse were injected via tail vein of 6-week-old male athymic nu/nu mice (Charles River Japan Inc.). At 28 days after tumor cell injection, mice were randomly assigned to receive PBS or with 5 Â 10 8 PFU of Ad-DB7 or Ad-DB7-U6shIL8 in 100 ml of PBS three times every other day by intrapleural injection. At days 3 and 28 post-final viral injection, blood samples were obtained by cardiac puncture. Lungs were excised and tumor nodules were counted. For toxicological evaluation, blood samples were analyzed for the serum levels of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase and T-bilirubin to assess liver function, and blood urea nitrogen and creatinine for kidney function. In addition, lung tissues were fixed in formalin-free IHC zinc fixative formalin-free (BD Biosciences PharMingen) for 2 days, and 3-mm tissue sections were cut and stained with either H&E, M&T, anti-E1A or anti-CD31.
Statistical analysis
The data are expressed as mean ± s.e., and the significance of differences between group means was determined by the Mann-Whitney test (non-parametric rank sum test) using Stat View software (Abacus Concepts Inc., Berkeley, CA, USA). Differences were considered significant when Po0.05.
